343 related articles for article (PubMed ID: 37036582)
41. Preclinical rationale for use of the clinically available multitargeted tyrosine kinase inhibitor crizotinib in ROS1-translocated lung cancer.
Yasuda H; de Figueiredo-Pontes LL; Kobayashi S; Costa DB
J Thorac Oncol; 2012 Jul; 7(7):1086-90. PubMed ID: 22617245
[TBL] [Abstract][Full Text] [Related]
42. Cabozantinib overcomes crizotinib resistance in ROS1 fusion-positive cancer.
Katayama R; Kobayashi Y; Friboulet L; Lockerman EL; Koike S; Shaw AT; Engelman JA; Fujita N
Clin Cancer Res; 2015 Jan; 21(1):166-74. PubMed ID: 25351743
[TBL] [Abstract][Full Text] [Related]
43. Crizotinib, a small-molecule dual inhibitor of the c-Met and ALK receptor tyrosine kinases.
Rodig SJ; Shapiro GI
Curr Opin Investig Drugs; 2010 Dec; 11(12):1477-90. PubMed ID: 21154129
[TBL] [Abstract][Full Text] [Related]
44. Non-Small Cell Lung Cancer Cells Acquire Resistance to the ALK Inhibitor Alectinib by Activating Alternative Receptor Tyrosine Kinases.
Isozaki H; Ichihara E; Takigawa N; Ohashi K; Ochi N; Yasugi M; Ninomiya T; Yamane H; Hotta K; Sakai K; Matsumoto K; Hosokawa S; Bessho A; Sendo T; Tanimoto M; Kiura K
Cancer Res; 2016 Mar; 76(6):1506-16. PubMed ID: 26719536
[TBL] [Abstract][Full Text] [Related]
45. SHP2 Inhibition Enhances the Effects of Tyrosine Kinase Inhibitors in Preclinical Models of Treatment-naïve
Kano H; Ichihara E; Watanabe H; Nishii K; Ando C; Nakasuka T; Ninomiya K; Kato Y; Kubo T; Rai K; Ohashi K; Hotta K; Tabata M; Maeda Y; Kiura K
Mol Cancer Ther; 2021 Sep; 20(9):1653-1662. PubMed ID: 34158345
[TBL] [Abstract][Full Text] [Related]
46. An updated patent review of small-molecule ROS1 kinase inhibitors (2015-2021).
Liu M; Dai J; Wei M; Pan Q; Zhu W
Expert Opin Ther Pat; 2022 Jun; 32(6):713-729. PubMed ID: 35343863
[TBL] [Abstract][Full Text] [Related]
47. ALK rearrangements are mutually exclusive with mutations in EGFR or KRAS: an analysis of 1,683 patients with non-small cell lung cancer.
Gainor JF; Varghese AM; Ou SH; Kabraji S; Awad MM; Katayama R; Pawlak A; Mino-Kenudson M; Yeap BY; Riely GJ; Iafrate AJ; Arcila ME; Ladanyi M; Engelman JA; Dias-Santagata D; Shaw AT
Clin Cancer Res; 2013 Aug; 19(15):4273-81. PubMed ID: 23729361
[TBL] [Abstract][Full Text] [Related]
48. Construction of crizotinib resistant models with CD74-ROS1 D2033N and CD74-ROS1 S1986F point mutations to explore resistance mechanism and treatment strategy.
Sun R; Meng Y; Xu R; Li Y; Xu X; Li Z; Zuo D
Cell Signal; 2023 Jan; 101():110497. PubMed ID: 36265718
[TBL] [Abstract][Full Text] [Related]
49. The new-generation selective ROS1/NTRK inhibitor DS-6051b overcomes crizotinib resistant ROS1-G2032R mutation in preclinical models.
Katayama R; Gong B; Togashi N; Miyamoto M; Kiga M; Iwasaki S; Kamai Y; Tominaga Y; Takeda Y; Kagoshima Y; Shimizu Y; Seto Y; Oh-Hara T; Koike S; Nakao N; Hanzawa H; Watanabe K; Yoda S; Yanagitani N; Hata AN; Shaw AT; Nishio M; Fujita N; Isoyama T
Nat Commun; 2019 Aug; 10(1):3604. PubMed ID: 31399568
[TBL] [Abstract][Full Text] [Related]
50. ROS1-ADGRG6: a case report of a novel ROS1 oncogenic fusion variant in lung adenocarcinoma and the response to crizotinib.
Xu S; Wang W; Xu C; Li X; Ye J; Zhu Y; Ge T
BMC Cancer; 2019 Aug; 19(1):769. PubMed ID: 31382924
[TBL] [Abstract][Full Text] [Related]
51. ALK inhibitors: what is the best way to treat patients with ALK+ non-small-cell lung cancer?
Toyokawa G; Seto T
Clin Lung Cancer; 2014 Sep; 15(5):313-9. PubMed ID: 24984564
[TBL] [Abstract][Full Text] [Related]
52. ROS1 rearrangements define a unique molecular class of lung cancers.
Bergethon K; Shaw AT; Ou SH; Katayama R; Lovly CM; McDonald NT; Massion PP; Siwak-Tapp C; Gonzalez A; Fang R; Mark EJ; Batten JM; Chen H; Wilner KD; Kwak EL; Clark JW; Carbone DP; Ji H; Engelman JA; Mino-Kenudson M; Pao W; Iafrate AJ
J Clin Oncol; 2012 Mar; 30(8):863-70. PubMed ID: 22215748
[TBL] [Abstract][Full Text] [Related]
53. Discovery of novel 2-aminopyridine derivatives as ROS1 and ALK dual inhibitors to combat drug-resistant mutants including ROS1
Liu S; Huang C; Huang C; Huang Y; Yu Y; Wu G; Guo F; Jiang Y; Wan S; Zhu Z; Tian Y; Zhu J; Zhang J
J Enzyme Inhib Med Chem; 2023 Dec; 38(1):2227779. PubMed ID: 37349867
[TBL] [Abstract][Full Text] [Related]
54. Targeting CCR7-PI3Kγ overcomes resistance to tyrosine kinase inhibitors in ALK-rearranged lymphoma.
Mastini C; Campisi M; Patrucco E; Mura G; Ferreira A; Costa C; Ambrogio C; Germena G; Martinengo C; Peola S; Mota I; Vissio E; Molinaro L; Arigoni M; Olivero M; Calogero R; Prokoph N; Tabbò F; Shoji B; Brugieres L; Geoerger B; Turner SD; Cuesta-Mateos C; D'Aliberti D; Mologni L; Piazza R; Gambacorti-Passerini C; Inghirami GG; Chiono V; Kamm RD; Hirsch E; Koch R; Weinstock DM; Aster JC; Voena C; Chiarle R
Sci Transl Med; 2023 Jun; 15(702):eabo3826. PubMed ID: 37379367
[TBL] [Abstract][Full Text] [Related]
55. Discovery of Entrectinib: A New 3-Aminoindazole As a Potent Anaplastic Lymphoma Kinase (ALK), c-ros Oncogene 1 Kinase (ROS1), and Pan-Tropomyosin Receptor Kinases (Pan-TRKs) inhibitor.
Menichincheri M; Ardini E; Magnaghi P; Avanzi N; Banfi P; Bossi R; Buffa L; Canevari G; Ceriani L; Colombo M; Corti L; Donati D; Fasolini M; Felder E; Fiorelli C; Fiorentini F; Galvani A; Isacchi A; Borgia AL; Marchionni C; Nesi M; Orrenius C; Panzeri A; Pesenti E; Rusconi L; Saccardo MB; Vanotti E; Perrone E; Orsini P
J Med Chem; 2016 Apr; 59(7):3392-408. PubMed ID: 27003761
[TBL] [Abstract][Full Text] [Related]
56. ALK and ROS1 as targeted therapy paradigms and clinical implications to overcome crizotinib resistance.
Ye M; Zhang X; Li N; Zhang Y; Jing P; Chang N; Wu J; Ren X; Zhang J
Oncotarget; 2016 Mar; 7(11):12289-304. PubMed ID: 26802023
[TBL] [Abstract][Full Text] [Related]
57. Activation of IGF-1R pathway and NPM-ALK G1269A mutation confer resistance to crizotinib treatment in NPM-ALK positive lymphoma.
Li Y; Wang K; Song N; Hou K; Che X; Zhou Y; Liu Y; Zhang J
Invest New Drugs; 2020 Jun; 38(3):599-609. PubMed ID: 31177400
[TBL] [Abstract][Full Text] [Related]
58. Resistance to Crizotinib in Advanced Non-Small Cell Lung Cancer (NSCLC) with ALK Rearrangement: Mechanisms, Treatment Strategies and New Targeted Therapies.
Casaluce F; Sgambato A; Sacco PC; Palazzolo G; Maione P; Rossi A; Ciardiello F; Gridelli C
Curr Clin Pharmacol; 2016; 11(2):77-87. PubMed ID: 27138017
[TBL] [Abstract][Full Text] [Related]
59. Mechanisms of suppression of cell growth by dual inhibition of ALK and MEK in ALK-positive non-small cell lung cancer.
Shrestha N; Nimick M; Dass P; Rosengren RJ; Ashton JC
Sci Rep; 2019 Dec; 9(1):18842. PubMed ID: 31827192
[TBL] [Abstract][Full Text] [Related]
60. Biomarker guided treatment in oncogene-driven advanced non-small cell lung cancer in older adults: A Young International Society of Geriatric Oncology report.
Christofyllakis K; Monteiro AR; Cetin O; Kos IA; Greystoke A; Luciani A
J Geriatr Oncol; 2022 Nov; 13(8):1071-1083. PubMed ID: 35525790
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
